Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optic Nerve Head Strain in Non-glaucoma Subjects
NCT07425535Phase 1Recruiting
- Sponsor
- Johns Hopkins University
- Start
- Jun 2026
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of latanoprost ophthalmic solution 0.005% (TearClear TC-002) in Glaucoma, sponsored by Johns Hopkins University. Primary endpoint: Optic nerve head strain at 1 month. Started Jun 2026; status: recruiting.
02
Drugs
latanoprost ophthalmic solution 0.005% (TearClear TC-002)
03
Conditions
Glaucoma
Beyond the preview
Go deeper on NCT07425535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07425535.